Glucose-6-Phosphate Dehydrogenase Deficiency

← Back to Index(🩸 Hematology and Oncology)

Genetics and Epidemiology

Pathophysiology

World Health Organization Classification

Class Variant Examples Enzyme Activity Hemolysis Severity
Class I Harilaou, tokyo, guadalajara Less than 2% of normal Severe chronic nonspherocytic hemolytic anemia
Class II Mediterranean, canton Less than 10% of normal Intermittent severe acute hemolysis
Class III A- (african) 10-60% of normal Intermittent mild hemolysis with drugs or infections
Class IV B (normal) 100% of normal No hemolysis

[Source: 417, 637]

Clinical Manifestations

Asymptomatic State

Episodic Acute Hemolytic Anemia

Favism

Neonatal Jaundice

Chronic Nonspherocytic Hemolytic Anemia

Oxidant Drug Triggers

Drug Category Specific High-Risk Agents
Antimalarials Primaquine, dapsone, tafenoquine, pamaquine
Antibiotics Sulfamethoxazole, nitrofurantoin, nalidixic acid, ciprofloxacin, norfloxacin
Analgesics Phenazopyridine (pyridium), acetanilid
Miscellaneous Rasburicase, pegloticase, methylene blue, toluidine blue, glibenclamide

[Source: 40, 41, 639, 644] Note: standard doses of aspirin and trimethoprim-sulfamethoxazole typically do not cause clinically relevant hemolysis in the a- variant, though high-dose aspirin may produce severe episodes.

Laboratory Investigations

Primary Hematology

Peripheral Blood Smear

Supravital Staining

Hemolysis Markers

Diagnostic Enzyme Assays

Management

Preventive Strategies

Acute Hemolytic Crisis

Neonatal Jaundice

Chronic Nonspherocytic Hemolytic Anemia